The neurotensin receptors are overexpressed in various tumor types, especially in highly progressive pancreatic tumors. As this cancer has a poor 5-year survival prognosis, there is an urgent need to improve early diagnosis and treatment strategies. This review article provides an overview of the latest developments in radiopharmaceuticals for neurotensin receptor-positive tumors, including peptidic and non-peptidic radiopharmaceuticals, not only for SPECT and PET but also for endoradiotherapy.
Keywords: NTS1; PET; SPECT; endoradiotherapy; neurotensin; neurotensin receptor; pancreatic tumor.
Copyright © 2017 John Wiley & Sons, Ltd.